Albright Charles 4
4 · Editas Medicine, Inc. · Filed Aug 19, 2020
Insider Transaction Report
Form 4
Albright Charles
Chief Scientific Officer
Transactions
- Sale
Common Stock
2020-08-17$35.29/sh−10,000$352,900→ 28,135 total - Exercise/Conversion
Common Stock
2020-08-17$16.51/sh+10,000$165,100→ 38,135 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-17−10,000→ 185,000 totalExercise: $16.51Exp: 2026-09-08→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
- [F2]This transaction was executed in multiple trades at prices ranging from $35.00 to $35.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020.